This is the first installment — the Prologue — of our six-part “ASCO 2026 in Review” series, a panoramic look at the 2026 ASCO Annual Meeting (American Society of Clinical Oncology). Held over five days at Chicago’s McCormick Place from May 29 to June 2, 2026, this meeting redrew, on a single map, the question of where the world’s oncology is heading. Rather than dissecting individual trials at the level of a journal paper, this series focuses on charting the “map of trends” — which direction cancer treatment moved in 2026 — and on reading its meaning and what comes next. As the Prologue, this piece serves as a preview hub for the forthcoming Vol. 2 through 6: RAS, antibody-drug conjugates (ADCs), bispecific antibodies, GLP-1 and metabolism, and finally globalization/AI.
What Is ASCO, Anyway — Why the World’s Oncology Gathers Once a Year
If you follow cancer news, every early summer the four letters “ASCO” suddenly fill the airwaves. ASCO (the American Society of Clinical Oncology) is the world’s most influential professional body in oncology, and its Annual Meeting is positioned as the single most important venue for unveiling new drugs and new treatment strategies. Pharmaceutical companies present here, for the first time to the world, the results of Phase 3 trials into which they have poured hundreds of millions of dollars — often around the time of regulatory submission. In other words, ASCO is where physicians, researchers, and investors worldwide simultaneously witness the moment a “laboratory discovery” becomes “tomorrow’s clinical practice.”
Why does it carry such weight? Because the “ranking” of presentations is highly structured. For newcomers, it helps to lay out how the system works.
- Plenary Session: The main session that gathers the meeting’s most important abstracts. Out of thousands of submissions, only a handful are chosen, presenting results judged to be practice-changing. In 2026, five abstracts — LBA1 through LBA5 — were selected.
- Late-Breaking Abstract (LBA): Top-tier results whose final data matured after the abstract submission deadline, marked with the “LBA” prefix. Think of it as a designation reserved for abstracts that satisfy both timeliness and importance.
- Regular Abstracts: A vast number of research reports including oral and poster presentations. This is where the “thickness” of a trend lives — any single one may not make headlines, but read together, a direction emerges.
- Education Session: A forum for discussing how to translate the latest evidence into clinical practice. This year, the clinical implementation of AI became a major theme.
This hierarchy is precisely what makes ASCO more than a mere accumulation of conference talks — it is oncology’s “consensus-building engine.” Being selected for the Plenary is close to an official recognition that a study has “added a page to the history of cancer treatment.” That is why pharmaceutical stock prices move sharply during ASCO and why the media race to break the news. Our decision to avoid colliding head-on with the breaking-news cycle, and instead to draw a map that can only be built through integration, analysis, lineage, and competitive structure, is meant to capture the “meaning” that remains after the festival.
There is one more perspective worth conveying to newcomers. A result presented at ASCO does not, by itself, settle the “right answer.” Rather, the meeting is a starting point for experts worldwide to debate how to interpret the data and how to change their own practice — or whether to change it at all. Even for the same Phase 3 trial, questions such as “was the comparator realistic?”, “is the magnitude of benefit clinically meaningful?”, and “how does it balance against side effects?” are exchanged within the expert community immediately after presentation. That is why, rather than chasing the glamorous Plenary numbers alone, reading the context in which those numbers sit — in which patients, against which existing treatment, with how much added benefit — is the key to grasping a trend correctly. Our consistent emphasis on “the meaning of the numbers” over “the numbers themselves” is for exactly this reason.
The Theme of “Translation” — A Single Thread Running Through 2026
The 2026 meeting carried an explicit theme: “The Science and Practice of Translation: Improving Cancer Outcomes Worldwide.” This was the year-long banner raised by 2025–2026 ASCO President Dr. Eric J. Small.
The “Translation” invoked here has multiple layers. First, translation from the laboratory to the clinic — converting basic-science discoveries into treatments that actually reach patients. Second, translation from clinical trials to real-world care — applying results obtained under idealized trial conditions to the diverse patients of everyday practice. And third, translation that delivers innovation to every patient — carrying breakthroughs across barriers of culture, language, geography, and economic disparity to reach people worldwide. In Dr. Small’s framing, even excellent science fails to benefit patients unless it is “translated.”
This theme is more than a coincidental slogan for reading the 2026 presentations. As we will see, this year’s major topics — RAS, the “undruggable” target that fell; ADCs, which broke through the tumor-type barrier; bispecific antibodies, which are rewriting the conventions of immunotherapy; GLP-1, which cuts into oncology from the new field of metabolism; and globalization/AI, which asks about the “last mile” of delivering breakthroughs worldwide — each embodies a different facet of “translation.” The advance of the science itself and the implementation question of to whom, and how, it is delivered were discussed with equal weight at the same meeting. That was the atmosphere of ASCO 2026.
Behind the choice of “translation” as a theme lies a quiet unease in recent oncology. Over the past decade, the science of cancer treatment has advanced dramatically. Immune checkpoint inhibitors, CAR-T, precision medicine — at the research frontier, “effective” treatments keep emerging. Yet ask whether those benefits reach patients worldwide equally, and the answer is plainly “no.” For the same diagnosis, the treatment one can receive differs greatly by country and region, by income and insurance, by race and ethnicity. Even when a cutting-edge drug is approved, there are regions where it is out of reach for the majority simply because the price is too high. What Dr. Small invested in the word “translation,” one can read, is a consciousness of this chasm lying between the “victory of science” and the “benefit to patients.” In placing that chasm squarely on the agenda, ASCO 2026 carried meaning beyond a mere showcase of new drugs.
A Panorama of the Five Plenary Abstracts — What Stood at the 2026 Summit
Let us first survey the five Plenary abstracts (LBA1–LBA5) that stood at this year’s summit. Deep dives into each are left to later installments and dedicated features; here we present the map of “what comes into view when the five are placed side by side.”
| Abstract | Trial | Setting | Summary |
|---|---|---|---|
| LBA1 | PROTEUS | High-risk prostate cancer | Perioperative apalutamide + ADT + radical prostatectomy roughly multiplied the pathologic complete response rate and prolonged event-free survival. A new standard-of-care candidate. |
| LBA2 | SARC-041 | Advanced dedifferentiated liposarcoma | CDK4 inhibitor abemaciclib delivered median PFS of 9.7 vs 1.5 months, a 62% reduction in progression/death risk. The first positive Phase 3 in this rare sarcoma. |
| LBA3 | LIBRETTO-432 | Early-stage RET fusion-positive NSCLC | Adjuvant selpercatinib reduced recurrence/death risk by 83%. The first adjuvant targeted therapy for this subset. |
| LBA4 | HARMONi-6 | Untreated advanced squamous NSCLC | Bispecific ivonescimab (PD-1×VEGF) plus chemotherapy was superior in OS to a PD-1 antibody plus chemotherapy (HR 0.66). |
| LBA5 | RASolute-302 | Metastatic pancreatic ductal adenocarcinoma | Pan-RAS inhibitor daraxonrasib monotherapy significantly improved OS, PFS, and ORR over chemotherapy — roughly a 60% reduction in death risk. |
Placing these five side by side, several structures emerge. First, a “shift toward early and perioperative settings.” PROTEUS (prostate) and LIBRETTO-432 (lung) both deploy potent agents not in advanced disease but in patients at an earlier, potentially curable stage, aiming to suppress recurrence and metastasis. Targeted and endocrine therapies are expanding their role from end-stage life extension toward “adding to the chance of cure.”
Second, “the fall of formidable foes.” The target of RASolute-302, pancreatic ductal adenocarcinoma (PDAC), has long been described as having the worst prognosis and as a setting where RAS was “undruggable.” That a pan-RAS inhibitor, as monotherapy, surpassed chemotherapy there is a symbolic turning point. SARC-041’s dedifferentiated liposarcoma is likewise a rare cancer once considered to have no effective drug — sharing the theme that “we finally reached places where nothing could be done before.”
Third, “tectonic shifts in the global drug-development map.” HARMONi-6’s ivonescimab is one symbol of China-originated bioinnovation; according to reports, it marked the first time in ASCO’s 61-year history that a China-originated investigational drug was selected for the Plenary. The most prestigious stage acknowledged that the center of gravity in drug development is shifting from a US-Europe monopoly toward a multipolar landscape. This connects directly to the last of the five turning points discussed below — globalization.
Pulling back further, the five Plenary abstracts are beautifully dispersed in terms of modality as well. PROTEUS and SARC-041 show new ways of using existing drugs — a strategy of bringing apalutamide (endocrine therapy) and abemaciclib (a relatively established small molecule, a CDK4 inhibitor) into disease stages and tumor types where they had not been used before. LIBRETTO-432 represents the move of targeted therapy into the adjuvant setting; RASolute-302, the breaking of a target long deemed undruggable; and HARMONi-6, an entirely new molecular design through antibody engineering. In other words, different kinds of innovation — not just “making new drugs,” but “deploying existing weapons on new battlefields,” “challenging targets once thought impossible,” and “redesigning the molecule itself” — stood together at the same summit. This tells us that progress in cancer treatment no longer depends on any single technological breakthrough. What each subsequent installment digs into is precisely the question of where this “parallel advance of diverse innovations” is heading.
The “Five Turning Points” of 2026 — A Map to the Series Ahead
The Plenary is, after all, the “summit” — not the full picture of the trends. Reading the vast body of regular abstracts and expert commentary together, five turning points come into view for cancer treatment in 2026. Vol. 2 through 6 of this series are each structured to take a deep dive into one of these turning points. Here we sketch only the outline of each, reserving the deep dives for later installments.
Turning Point 1: RAS — The Fall of the “Undruggable” Target (→ Vol. 2)
The oncogene RAS is mutated in roughly 30% of all cancers, yet for nearly 40 years it was synonymous with “undruggable.” Why was it deemed impossible? Because the surface of the RAS protein is smooth, offering almost no “pocket” for a drug to grip, and because it competes fiercely with other essential proteins in the body — making it extremely hard to suppress with a drug. That wall is now crumbling along the lineage of KRAS G12C (sotorasib/adagrasib) → G12D → pan-RAS. The first breakthrough came from agents narrowly targeting the specific G12C mutation, but the 2026 symbol is that the pan-RAS inhibitor daraxonrasib, which broadly suppresses RAS regardless of mutation type, surpassed chemotherapy in PDAC (RASolute-302, Plenary LBA5). Beyond that, expert commentary reported that a cohort of next-generation KRAS G12D inhibitors — zoldonrasib, INCB161734, ASP3082, and HRS-4642 — showed promising efficacy without dose-limiting toxicity. The “five arrows to come” are assembling. That an “effective” drug emerged in pancreatic cancer — one of the worst-prognosis malignancies — carries meaning beyond the numbers. Vol. 2 details this lineage and competitive structure.
Turning Point 2: ADCs — Precision Strikes Across the Tumor-Type Barrier (→ Vol. 3)
ADCs (antibody-drug conjugates) use the antibody for “aim” and the conjugated drug (payload) for “destruction” — in effect, pinpoint strikes on cancer cells. The 2026 highlight was the first Phase 3 in which an ADC plus a checkpoint inhibitor outperformed a checkpoint inhibitor alone (TROP2 ADC Sac-TMT plus pembrolizumab, OptiTROP-Lung05). Targets are broadening to TROP2, HER2, HER3, B7-H3, and B7-H4, and the payload of choice is increasingly TOP1 inhibition (the DXd class). The TROP2 ADC competition typified by Dato-DXd vs Trodelvy is also intensifying. The fascination of ADCs lies in the fact that, by recombining three components — the antibody (aim), the linker (the connecting part), and the payload (the drug) — one can, in theory, create countless combinations. Which target to aim at, which linker to stabilize it, which payload to destroy with — this design freedom is what now intensifies the development race among pharmaceutical companies. 2026 was also the year that competition evolved into a tumor-type-spanning contest over “in which cancer type one wins.” Vol. 3 charts “the drug-development map read through the race for targets.”
Turning Point 3: Bispecific Antibodies — Challenging the “Keytruda Ceiling” (→ Vol. 4)
Bispecific antibodies, which grip two targets simultaneously with a single molecule, pushed the design philosophy of immunotherapy up a level. Until now, the convention was to combine immunotherapy and anti-angiogenic therapy as separate drugs; bispecific antibodies integrate them into one molecule. The Plenary’s ivonescimab (PD-1×VEGF) integrates immune checkpoint blockade (PD-1) and anti-angiogenesis (VEGF) into one molecule, taking a head-on challenge in squamous NSCLC against the “Keytruda (pembrolizumab) ceiling” that has capped PD-1-based regimens. Crucially, this trial was not a “comparison against chemotherapy” but a “head-to-head against a sitting standard immunotherapy.” For years, no drug had clearly beaten a PD-1-based regimen. That a new-generation molecule with a different design philosophy challenged that stronghold and showed superiority in overall survival is highly significant. Development of this molecular class is advancing at multiple companies, and competition is fierce. In Vol. 4, rather than the thickness of raw data, we emphasize design philosophy, competitive structure, and forward-looking analysis.
Turning Point 4: GLP-1 and Metabolism — The New Battlefield of “Metabolism × Oncology” (→ Vol. 5)
GLP-1 receptor agonists, which spread as treatments for obesity and diabetes, have begun to connect to oncology in unexpected ways. In 2026, real-world data on more than 10,000 cases showed signals of suppressed metastatic progression and improved overall survival across multiple cancer types, with concrete reports in HR+ breast cancer, endometrial cancer, and others. A new field of “metabolic oncology,” rooted in the obesity-cancer link, is taking shape. That obesity is a risk factor for several cancers has long been known; but whether a “weight-loss drug” can change cancer progression or survival is a question to which large-scale data have begun to return a partial answer. Caution is warranted, however: much of this is retrospective real-world data, not randomized controlled trials. Mistaking “correlation” for “causation” could invite excessive expectations or misguided clinical decisions. Vol. 5 organizes the state of play on this battlefield and the reasons to avoid overstatement.
Turning Point 5: Globalization/AI — The “Last Mile” of Delivering Breakthroughs (→ Vol. 6)
This is the domain where the theme of “translation” appeared most directly. Affordable oral regimens for low-resource settings, maintenance therapy framed around cost and access, early detection via liquid biopsy (cfDNA fragmentomics), the renewal of lung-cancer screening criteria, and AI × oncology in digital pathology and clinical implementation — all were bundled around the implementation question of delivering scientific breakthroughs to “every patient.” Vol. 6 discusses how equity, liquid biopsy, and AI are rewriting the implementation of cancer care, bringing the series to a close.
What the “Trials That Didn’t Work” Teach Us — The Meaning of Three Negative Results
ASCO coverage inevitably concentrates on dazzling positive results. But drawing an accurate map requires reading the “trials that didn’t work.” Negative results protect patients from futile treatment, correct the direction of the next hypothesis, and put the brakes on excessive expectations. In the world of clinical trials, a report that something “did not work” is, as knowledge, just as important as a report that it “worked” — yet the former is hidden behind positive results, less reported, and at times even less likely to be published (publication bias). That is precisely why, from a vantage point surveying trends, there is value in deliberately picking up negative results. Here are three from 2026 worth noting.
- RAMPART: Adjuvant durvalumab monotherapy in intermediate-to-high-risk renal cell carcinoma (RCC) did not improve disease-free survival (DFS), showing that post-operative adjuvant immunotherapy does not work “everywhere.”
- ALCHEMIST EA5142: Adjuvant nivolumab in resected non-small cell lung cancer (NSCLC) did not improve DFS regardless of PD-L1 status, underscoring once again the importance of selecting the right patients by biomarker.
- PLUDO: In metastatic castration-resistant prostate cancer (mCRPC), Lu-177-PSMA-617 compared with docetaxel showed no difference in rPFS or OS, demonstrating that a new modality (radioligand therapy) does not necessarily surpass existing drugs.
What these three share is the fact that an expected intervention failed to add benefit in a specific population or a specific setting. Whereas positive Plenary results show “where we can advance,” negative results teach “where we should stop” and “whom we should select.” A warning against viewing immunotherapy as a panacea, the imperative of biomarker selection, and a sober appraisal of new modalities — these three messages, behind the excitement of positive results, will act quietly but surely on clinical practice in 2026. A good map charts not only the roads forward but also the dead ends, accurately.
How to Read the Five Turning Points Together — 2026 as an Intersection
We have drawn the five turning points individually, but the real reward of this series lies in the fact that they intersect with one another. A map of trends is richest when read not as a collection of solitary roads but as a network of intersections.
The clearest intersection is the fusion of ADCs (Vol. 3) and bispecific antibodies (Vol. 4). The two have developed as separate technological lineages, but in 2026 several “bispecific ADCs” — bispecific antibodies fitted with a payload — were reported. Loading a cell-destroying drug onto an antibody that grips two targets at once is, in effect, the union of “precision guidance” and “precision strike.” This symbolizes that the boundaries of modalities are beginning to dissolve; reading Vol. 3 and Vol. 4 with cross-reference reveals a convergence of design philosophy invisible in either article alone.
Another intersection lies between RAS (Vol. 2) and immunity/metabolism (Vol. 4 and Vol. 5). RAS mutations are known to affect the tumor’s immune environment and metabolism as well, and how to combine RAS inhibitors with immunotherapy or metabolic intervention will be a major question of the coming years. What follows breaking the wall with monotherapy is, inevitably, the second act of “optimizing combinations.” And finally, all these technological advances converge on the implementation layer of globalization/AI (Vol. 6). However refined the molecular design, it cannot avoid the question of who can receive it, where, and at what cost. This series is designed as a journey that travels once around this network of intersections.
Closing the Prologue — A Map of the Modality Revolution
If ASCO 2026 had to be summarized in a single phrase, it would be “the year modalities evolved simultaneously on many fronts.” Small molecules (RAS inhibition), antibody-drug conjugates (ADCs), bispecific antibodies, and the entry of metabolism — a “non-cancer” domain (GLP-1) — treatments built on different principles all advanced at once, each on its own front. And every one of them ultimately connects to the globalization/AI implementation question of “to whom, and how, do we deliver?” This is the true identity of the thread that the theme of “translation” ran through the year.
Starting from this overall map, this series will walk through the five turning points one by one. In the next installment, Vol. 2, we map how far RAS — long deemed the “undruggable target” — has fallen, including the pan-RAS targeting established in pancreatic cancer and the several development candidates coming next. With the panorama from this Prologue in hand, let us descend to the front lines of each battlefield.
My Thoughts and Future Outlook
The first thing I felt following this year’s ASCO was a sense that “cancer news can no longer be told through a single protagonist.” Until a few years ago, the single revolution of checkpoint inhibitors monopolized the conversation. But in 2026, RAS, ADCs, bispecific antibodies, and GLP-1 stood shoulder to shoulder in the same meeting, each carrying a different hope to a different patient. For newcomers, the sheer volume may be bewildering — yet I would read this “multipolarity” as evidence that cancer treatment is maturing.
From an expert’s vantage point, the real theme of 2026 is not any individual drug name but the single word the president raised: “translation.” That RAS fell in pancreatic cancer and that a China-originated bispecific antibody reached the Plenary mean that scientific advance has become geographically multipolar as well. At the same time, what the three failed trials quietly drove home is a question of “translation quality” — patient selection by biomarker, and sober verification of new modalities.
What is missing is clear. Between brilliant efficacy data and the access, cost, and implementation capacity needed to actually deliver them to every patient, a wide chasm remains. Over the next several years, the question will be less “does it work?” than “does it reach?” I hope this series can serve as a map for surveying that chasm.
This article is an independent summary and analysis by Morningglorysciences based on publicly available information from the 2026 ASCO Annual Meeting and related presentations. Always consult primary publications, the latest guidelines, and official prescribing information when making treatment decisions.
ASCO 2026 in Review — Series Index
This article is part of the six-part series “ASCO 2026 in Review.” For the full overview, start with Vol.1 Prologue (hub article). Each part stands alone but is designed to complement the others.
- Vol.1 Prologue: The Modality Revolution [Hub] (this article)
- Vol.2 RAS: The Undruggable Falls
- Vol.3 ADC: Crossing Tumor Barriers
- Vol.4 Bispecifics: PD-1 x VEGF
- Vol.5 GLP-1: Metabolic Oncology
- Vol.6 Finale: Equity, Liquid Biopsy & AI
Comments